82882-56-2

Basic information

• Product Name: Pyrimidine, 2-(1H-pyrazol-1-yl)- (9CI)
• Synonyms: Pyrimidine, 2-(1H-pyrazol-1-yl)- (9CI);2-(1H-pyrazol-1-yl)Pyrimidine
• CAS NO: 82882-56-2
• Molecular Formula: C₇H₆N₄
• Molecular Weight: 146.14934
• Product Categories: PYRIMIDINE
• Mol File: 82882-56-2.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Pyrimidine, 2-(1H-pyrazol-1-yl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrimidine, 2-(1H-pyrazol-1-yl)- (9CI)(82882-56-2)
• EPA Substance Registry System: Pyrimidine, 2-(1H-pyrazol-1-yl)- (9CI)(82882-56-2)

Safety Data

• Hazardous Substances Data: 82882-56-2(Hazardous Substances Data)

Upstream product

• 288-13-1 NH-pyrazole 
• 79-04-9 chloroacetyl chloride 
• 4595-60-2 2-bromopyrimidine 
• 1722-12-9 2-chloropyrimidine 
• 557-01-7 2-hydroxypyrimidine 

Downstream Products

• 857641-46-4 2-(4-bromo-1H-pyrazol-1-yl)pyrimidine 
• 1448310-20-0 1-(pyrimidin-2-yl)-1H-pyrazole-5-carboxylic acid 
• 438037-61-7 Pt(C₆F₅)2(pzpm) 
• 438037-63-9 Pd(C₆HF₄)2(pzpm) 
• 438037-59-3 Pd(C₆F₅)2(pzpm) 
• 852807-28-4 3-[4-(3-chlorophenyl)piperazin-1-yl]-1-[1-(pyrimidin-2-yl)-1H-pyrazol-4-yl]propan-1-one 

Relevant articles and documents

Synthesis, characterization and dynamic behavior of (π-allyl)palladium complexes with polydentate nitrogen ligands, evidence of a dissociative mechanism

New examples of the fluxional behavior of (η3-allyl)palladium complexes are described. Variable-temperature experiments and line-shape analysis of two (η3-allyl)palladium complexes containing 2-(1H-pyrazol-1-yl)azine ligands were performed in order to determine the activation free energies, enthalpies and entropies of the process. A dissociative mechanism pointing to a selective Pd-N cleavage is proposed on the basis of these results and NOE experiments above and below the coalescence temperature. VCH Verlagsgesellschaft mbH, 1996.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.